small molecule development

AgonOx is a cancer immunotherapy company developing TIL (tumor-infiltrating lymphocyte) therapies. It isolates and expands the CD39+CD103+ subset of a patient's tumor-infiltrating lymphocytes, the fraction that is tumor-reactive. Its lead program, AGX-148, is in Phase 1 in solid tumors, with additional cell therapy programs in IND-enabling studies. The company also identifies immunotherapy targets by studying human TIL isolated from tumor types, and designs recombinant proteins, antibodies, or small molecules to block and/or activate immune-specific path

antibody developmentimmunotherapy target identificationin-vitro human immune assaysmouse tumor modelsrecombinant protein developmentTIL isolation and expansion

Akanocure is a drug development company with a focus on orphan and unmet needs in oncology. Applying expertise throughout the drug discovery and development process, it creates novel small molecules intended to positively impact the lives of cancer patients. Its mission is to find therapeutic approaches that block metastatic processes, and it integrates chemical methodology development with classic drug discovery expertise through collaboration with industry leaders, academia, and government.

chemical methodology developmentchemistry platformdrug developmentdrug discovery

Arkana Therapeutics is an early-stage, Boulder-based drug discovery company developing oral small-molecule therapies for obesity and metabolic disease. Its platform draws on metabolic adaptations found in nature, such as those seen in animals that endure prolonged fasting and extreme weight fluctuations. The company has two programs: ARK-100, an oral small molecule acting on the brain to reduce calorie intake, and ARK-200, an early-development oral small molecule designed to increase energy expenditure.

drug discoveryin vitro and in vivo modelsmetabolomics

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. It is pioneering a precision medicine approach targeting specific TGF-β superfamily members and pathways in oncology, inflammatory/immune, fibrotic, and metabolic diseases.

biologics developmentbiomarker stratificationdrug discoveryPK/PD modelingprecision medicinepreclinical development

Endobios Biotech is an EU-based startup advancing a potential first-in-class small molecule anticonvulsant, currently in the early preclinical stages of drug development. Its lead candidate ENB-002 is a new chemical scaffold (molecular weight <300 g/mol) based on unpublished fungal-derived compounds, with in vivo anticonvulsant activity in a mouse model, preliminary blood-brain barrier permeability data, and secondary capacity against neuropathic pain.

drug discoverypreclinical drug development